Pfizer starts evaluation of SARS-CoV-2 oral antiviral

By The Science Advisory Board staff writers

March 24, 2021 -- Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and efficacy of multiple ascending doses of the drug candidate.

PF-07321332 is the first orally administered novel coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies, according to the company. The treatment can potentially be given as an oral therapy at the first signs of infection, without requiring that patients are hospitalized.

The announcement comes after the dosing of single ascending doses of the SARS-CoV-2-3CL protease inhibitor candidate was completed in healthy adults. PF-07321332 has demonstrated potent in vitro antiviral activity against SARS-CoV-2, as well as activity against other coronaviruses, suggesting its potential for use in treating COVID-19.

Pyxis licenses 2 oncology ADC programs from Pfizer
Pyxis Oncology has entered into a worldwide license agreement with Pfizer for the development and commercialization of two antibody-drug conjugate (ADC)...
Pfizer-BioNTech study supports 97% effectiveness of COVID-19 vaccine
Real-world evidence released by the Israel Ministry of Health demonstrates dramatically lower incidence rates of COVID-19 disease in individuals fully...
Pfizer, BioNTech study 3rd booster of vaccine to protect against variants
Pfizer and BioNTech have started to evaluate the safety and immunogenicity of a third dose of their COVID-19 vaccine BNT162b2 as a booster on immunity...
Seven Bridges to provide scRNAseq data management for Pfizer
Bioinformatics provider Seven Bridges has been selected by Pfizer to provide data management services for Pfizer's single-cell RNA sequencing (scRNAseq)...
U.S. opts for 100M more doses of Pfizer-BioNTech COVID-19 vaccine
The U.S. government has exercised its option for an additional 100 million doses of the Pfizer-BioNTech COVID-19 vaccine

Copyright © 2021

Interphex 2021
October 19-21
New York City, New York United States
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter